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The present work relates with developing long acting sustain release microspheres of ropinirole hydrochloride (RPN) for treatment of Parkinson’s disease, that will sustain drug release up to 1 month. Biodegradable microspheres of RPN were 
prepared by using two different polymers (poly lactic co glycolic acid [PLGA] 50:50 and PLGA 75:25) employing double 
emulsion (W/O/W) solvent evaporation method. Preliminary optimization of process parameter was done for concentration 
of polyvinyl alcohol (PVA) solution, stirring speed, temperature of PVA solution, ratio of the drug to polymer (D/P) and 
ratio of internal phase to external phase volume (IP/EP). All formulations were evaluated for particle size, percentage yield, 
entrapment efficiency (EE), shape etc. Formulation E3 and E4 shows maximum EE. % in vitro drug release per day of E3 and 
E4 batch was studied. The RPN was incorporated successfully in microspheres prepared with 0.5% w/v PVA at 8000 RPM 
stirring speed, 20°C processing temperature, 1:4 drug polymer ratio and 1:30 IP/EP ratio, which provides sustained release 
up to 4 weeks with better efficacy and patient compliance and can be employed as an alternative to existing oral medications.
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Parkinson’s disease is a chronic disorder for which 
lifelong treatment with antiparkinsons drugs is 
necessary. Antiparkinsons drugs are not readily accepted 
by patients, thus, non-compliance is common.[1,2] 
Microspheres made up of biodegradable polymers, 
can be injected with a syringe into the body and once 
injected, solidify to form a semi-solid depot.[3,4] They are 
considered as a useful therapeutic option in patients 
with parkinsonism who lack insight or are known 
to adhere poorly to oral medications. Long-acting 
injectable antiparkinsons drugs have demonstrated a 
number of advantages over oral medication, including 
stabilization of serum drug levels, avoidance of the 
first pass metabolism, assured medication delivery 
and well-controlled titration to lowest effective doses.
Long-acting injectables reduce variation between peak 
and trough levels and have lower peak concentrations 
that can reduce the incidence of adverse effects.[5,6] 
Depot formulations have been well tolerated and more 
efficacious than their oral equivalents. In view of the 
need to provide extended release of antiparkinson drugs 
for longer duration with better patient compliance, 
the present study has been directed toward the 
incorporation of antiparkinson drug, ropinirole 
hydrochloride (RPN) into polymeric biodegradable 
microspheres formulation.
MATERIALS AND METHODS
RPN was obtained as a gift sample from Hetero 
Drugs Pvt. Ltd., Hyderabad, India. Poly lactic co 
glycolic acid (PLGA) 50:50 (PUROSORB 5002 PDLG) 
was generously provided by PURAC Biopolymers, 
Netherland. PLGA 75:25 (RESOMER 752S) was gifted by 
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polyvinyl alcohol (PVA) were gifted by Loba Chemical Pvt. Ltd, 
Mumbai. All other chemicals used were of analytical grade.
RPN microsphere preparation using double emulsion 
solvent evaporation technique
RPN was dissolved in 1-2 ml distilled water. It was 
sonicated (Oscar Ultrasonics, Mumbai) for 3 min. with organic 
phase containing 5 ml of DCM and PLGA polymer (300 mg, 
400 mg, 500 mg) for 10 min, which forms (W/O) primary 
emulsion. The obtained primary emulsion (6 ml) was further 
emulsified with aqueous PVA solution (0.5, 1 and 2% w/v at 
different volumes viz. 300 ml, 180 ml, 120 ml) using high 
speed homogenizer (REMI, India) at varying speed (6000, 
8000, 10,000 rpm), which forms W/O/W secondary emulsion. 
The resultant solution was stirred for 4 h to evaporate the 
solvent completely. Further, the microspheres were washed 
with distilled water, filtered by vacuum filtration and kept 
in vacuum desiccators for 12 h. Dried microspheres were 
collected in well-labeled glass vials and stored at 2-8°C 
temperature.
In order to optimize the formula of the microspheres, the 
following process and formulation variable parameters were 
studied; PVA concentration, stirring speed of homogenizer, 
process temperature of PVA solution, drug: polymer ratio (D/P 
ratio) and ratio of internal phase/external phase volume (IP/
EP ratio).
Optimization of process parameters
PLGA loaded RPN microspheres were prepared by using double 
emulsion solvent evaporation by changing the concentration 
of EP of the secondary emulsion (PVA solution) as shown in 
Table 1. Based on the results obtained, concentration of PVA 
solution was fixed to 0.5% w/v and kept constant for further 
B1 to B6 batches. Further RPN microspheres batches were 
prepared by varying stirring speed (6000-10000 rpm) using 
high speed homogenizer (REMI, India) as shown in Table 2.
Batches C1 to C6 were prepared by fixing stirring speed to 
8000 rpm to optimize temperature of EP (PVA solution) as 
shown in Table 3. Batches D1 to D6 were prepared by fixing 
temperature of PVA solution at 20°C to optimize drug/
polymer (D/P) ratio as shown in Table 4.
Batches E1 to E6 were prepared by keeping PVA concentration 
0.5% and stirring speed 8000 rpm, temperature of PVA solution 
20°C and D/P ratio 1:4 to optimize IP (primary emulsion): EP 
volume of secondary emulsion ratio as shown in Table 5.












A1 100 300 0.5 25 44.3 75.3 Spherical
A2 100 300 0.5 30 46.7 78.5 Spherical
A3 100 300 1 18 30.4 72.8 Spherical
A4 100 300 1 21 32.4 70.2 Spherical
A5 100 300 2 12 25.8 68.9 Irregular
A6 100 300 2 16 27.2 68.4 Irregular













B1 100 300 6000 33.4 47.2 68.8 Spherical
B2 100 300 6000 27.8 48.2 68.5 Spherical
B3 100 300 8000 17.8 50.5 76.8 Spherical
B4 100 300 8000 17.6 49.6 76.5 Spherical
B5 100 300 10000 10.9 26.2 66.7 Irregular
PLGA: Poly lactic co glycolic acid, EE: Entrapment efficiency












C1 100 300 15 31.4 31.2 70.2 Irregular
C2 100 300 15 30.8 32.3 76.2 Irregular
C3 100 300 20 22.1 40.3 76.3 Spherical
C4 100 300 20 20.4 41.5 77.7 Spherical
C5 100 300 30 16.8 36.4 70.2 Irregular
C6 100 300 30 17.2 36.9 70.4 Irregular
PVA: Polyvinyl alcohol, PLGA: Poly lactic co glycolic acid, EE: Entrapment efficiency
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EVALUATION OF MICROSPHERES
Percent yield
Microspheres recovered at the end of preparation were weighed 








To calculate the entrapment efficiency % (EE), 10 mg prepared 
microspheres were dissolved in 2 ml DCM. Diluted up to 
10 ml with distilled water. This solution was subjected to 
centrifugation at 1000 rpm. Supernatant was filtered through 
0.45 μm filter. The absorbances of these solution was noted 
using ultraviolet (UV) spectrophotometric method at λ max 









The mean particle size of freshly prepared microsphere samples 
of each batch was determined by laser light scattering (model 
Mastersizer 2000, Malvern Instruments, Malvern, UK).
Surface morphology
Surface Morphology of E3 batch was studied by using 
scanning electron microscope (SEM) (Model: JEOL JSM-6360) 
with an accelerating voltage of 10 kV.
In vitro RPN release from microspheres
The in vitro drug release for batch E3 and E4 was performed in 
phosphate buffer, pH 7.4 release media under sink conditions 
on shaker incubator (Chromous Biotech.) at a constant 
temperature (37°C). Microspheres equivalent to RPN 56 mg 
were dispersed in 5 ml distilled water in dialysis bag, which 
is suspended in the volumetric flask containing 50 ml of 
release media and kept for shaking in shaker incubator. At the 
set points, 3 ml sample was removed by syringe for analysis 
through 0.45 μm mdi nylon filters for which the concentration 
was analyzed at 249 nm by UV spectrophotometer.[7-9]
RESULTS AND DISCUSSION
The most suitable method for encapsulation of hydrophilic 
drugs into PLGA microspheres is the double emulsification 
solvent evaporation technique.[10] The drug RPN, being water 
soluble, the double emulsification solvent evaporation 
method was selected.[11] Multiple studies demonstrate that 
PLGA can easily be formulated into the drug carrying devices 
as microspheres.[12-15]
Table 1 shows that the particle size of RPN loaded PLGA 
microspheres were inversely proportional to the concentration 
of PVA solution used as EP. Previous investigations suggests 
that increasing the PVA concentration in the continuous 
medium reduces the particle size of microspheres.[16,17] 
Increasing the PVA concentration leads to more PVA molecules 
overlaying the surface of the droplets and provided protection 
to the droplets against coalescence, which resulted in the 
production of smaller emulsion droplets (25-30 μm).
Further, highest % yield and %EE of 78.5% and 46.7% 
respectively was obtained for A2 batch prepared using PVA 
solution at 0.5% concentration. Thus for further batches 








D/P ratio Mean particle 
size (μm)
EE (%) Yield (%) Shape
D1 100 500 1:5 26.38 56.7 72.4 Spherical
D2 100 500 1:5 27.2 56.8 72.6 Spherical
D3 100 400 1:4 16.8 48.5 78.3 Spherical
D4 100 400 1:4 16.7 47.3 79.4 Spherical
D5 100 300 1:3 10.3 30.8 74.6 Irregular
D6 100 300 1:3 9.5 27.8 73.7 Irregular








IP/EP ratio Mean particle 
size (μm)
EE (%) Yield (%) Shape
E1 100 400 1:50 16.7 41.4 76.7 Spherical
E2 100 400 1:50 16.2 40.8 76.2 Spherical
E3 100 400 1:30 20.4 52.5 80.8 Spherical
E4 100 400 1:30 23.6 51.8 81.2 Spherical
E5 100 400 1:20 26.3 56.5 78.2 Spherical
E6 100 400 1:20 26.3 52.7 78 Spherical
PLGA: Poly lactic co glycolic acid, EE: Entrapment efficiency, IP/EP: Internal phase/external phase
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Table 2 indicates that an increase in stirring speed from 
6000 rpm to 10000 rpm decreases the microsphere size 
significantly from 33.4 μm to 10.9 μm, but the %EE was 
reduced to 26.2%. The speed was therefore fixed to an 
optimum level of 8000 rpm for further batches.
At a higher temperature of PVA solution (30°C), it was 
observed that particle size was 17.2 μm and at 15°C of PVA 
solution particle size of microspheres was observed to be 
31.4 μm to. This is due to the fact that the W/O/W double 
emulsion at high temperatures is less viscous, thus it is much 
easier for the emulsion to be broken up into smaller droplets 
at the same input power of mixing.[18]
The EE was decreased at both higher temperature of external 
aqueous phase (30°C) and lower temperature (15°C) as 
compared to 20°C where EE of about 41% was observed. For 
further batches 20°C temperature of PVA solution was fixed. 
It was observed [Table 4] that EE was decreased from 56.6% to 
27.8% by changing D/P ratio from 1:5 to 1:3. The D/P ratio was 
fixed to 1:4 for further batches as at this ratio best EE% (78-79%) 
was achieved. Table 5 reveals that EE and particle size decreases 
as the ratio of IP to EP was increased from 1:20 to 1:50. An 
increase in the volume of the EP of the secondary emulsion 
led to a decrease in the particle size of microspheres. The 
droplet size of the secondary emulsion may decrease because 
of a decrease in the frequency of collision of droplets with an 
increase in the volume of the EP of the secondary emulsion.[16]
IP to EP was further fixed to 1:30 to produce optimum particle 
size and to achieve a better entrapment (52%). These optimized 
batches E3 and E4 were evaluated for percentage in vitro drug 
release by using dialysis bag method. Drug released through E3 
formulation containing PLGA 50:50 is 96% at the end of 28 days 
and more uniform than E4 formulation containing PLGA 75:25, 
where only 52% drug was released at the end of 28 days as shown 
in Figure 1. Polymer composition is the most important factor 
to determine the hydrophilicity and rate of degradation of a 
delivery matrix. A systematic study of the polymer composition 
with its degradation has been shown by many groups.[19,20]
PLGA 50:50 (PLA/PGA) exhibited a faster degradation than PLGA 
75:25 due to preferential degradation of glycolic acid proportion 
assigned by higher hydrophilicity.[20,21] SEM micrographs of E3 
formulation shows that PLGA 50:50 microspheres containing 
RPN are spherical in shape, having a smooth surface and size 
ranges from 20 to 25 μm as shown in Figure 2.
CONCLUSION
For a short-term release requirement (up to 1 month), an 
amorphous polymer PLGA 50:50 is recommended. For a 
longer-term release requirement (1-6 months), the choice of 
an amorphous polymer PLGA 75:25 would be appropriate. 
From this study is concluded that the RPN can be incorporated 
successfully in microspheres prepared with 0.5% w/v PVA 
at 8000 RPM stirring speed, 20°C processing temperature, 
1:4 drug polymer ratio and 1:30 IP/EP ratio, which provides 
sustained release up to 4 weeks with better efficacy and 
patient compliance and can be employed as an alternative 
to existing oral medications.
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